What is the role of arsenic in newly diagnosed APL?

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 4, 2008, Pages 659-666

  Tallman, Martin S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

acute promyelocytic leukemia; all trans retinoic acid; anthracyclines; APL; arsenic trioxide; ATO; ATRA; PML RAR ; tamibarotene

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; RETINOIC ACID; RETINOID; TAMIBAROTENE;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVATION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; TREATMENT OUTCOME; TRETINOIN;

EID: 56549086575     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.09.002     Document Type: Review

References (31)

1. Rodeghiero F., and Castaman G. The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. Leukemia 8 Suppl. 2 (1994) S20-S26
2. Asou N., Kishimoto Y., Kiyoi H., et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110 (2007) 59-66
3. Avvisati G., Petti M.C., Lo-Coco F., et al. AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act. Blood 102 (2003) 142a [abstract 487]
4. Ades L., Sanz M.A., Chevret S., et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 111 (2008) 1078-1084
5. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology 19 (2001) 3852-3860
6. Glienke W., Chow K.U., Bauer N., et al. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leukemia & Lymphoma 47 (2006) 1629-1638
7. Mathieu J., and Besancon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Annals of the New York Academy of Sciences 1090 (2006) 203-208
8. Ninomiya M., Kajiguchi T., Yamamoto K., et al. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica 91 (2006) 1571-1572
9. Powell B.L., Moser B., Stock W., et al. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. Journal of Clinical Oncology 25 (2007) 1s [abstract 2]
10. Liu Y.F., Zhu Y.M., Shi Z.Z., et al. Long-term follow-up confirms the benefit of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as front line therapy for newly diagnosed acute promyelocytic leukemia (APL). Blood 108 (2006) 170a [abstract 565]
11. Mathews V., George B., Lakshmi K.M., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107 (2006) 2627-2632
12. Ades L., Chevret S., Raffoux E., et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. Journal of Clinical Oncology 24 (2006) 5703-5710
13. Sanz M.A., Martin G., Gonzalez M., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103 (2004) 1237-1243
14. Shen Z.X., Shi Z.Z., Fang J., et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 5328-5335
15. Estey E., Garcia-Manero G., Ferrajoli A., et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107 (2006) 3469-3473
16. Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. Journal of Biological Regulators and Homeostatic Agents 13 (1999) 195-200
17. Ghavamzadeh A., Alimoghaddam K., Ghaffari S.H., et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Annals of Oncology 17 (2006) 131-134
18. Ghaffari S.H., Shayan-Asl N., Jamialahmadi A., et al. Telomerase activity and telomere length in APL: may be proliferative and prognosti markers. Blood 110 (2007) 126b [abstract 4236]
19. Mathews V., Thomas M., Srivastava V.M., et al. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica 92 (2007) 994-995
20. Alimoghaddam K., Ghavamzadeh A., Rostami S., et al. Risk factors for early mortality, relapse and overall survival in new cases of APL treated by arsenic trioxide. Journal of Clinical Oncology 25 (2007) 374s [abstract 7069]
21. Stock W., Najib K., Moser B.K., et al. High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): correlation with diagnostic features and treatment outcome (CALGB 9710). Journal of Clinical Oncology 26 (2008) 372s [abstract 7002]
22. Gale R.E., Hills R., Pizzey A.R., et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106 (2005) 3768-3776
23. Sainty D., Liso V., Cantu-Rajnoldi A., et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Group Francais de Cytogenetique Hematologique, UK Cancer Cytogenetics Group and BIOMED 1 European Coomunity-Concerted Acion "Molecular Cytogenetic Diagnosis in Haematological Malignancies. Blood 96 (2000) 1287-1296
24. Ito S., Ishida Y., Oyake T., et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leukemia & Lymphoma 45 (2004) 1783-1789
25. Douer D., Santillana S., Ramezani L., et al. Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene. British Journal of Haematology 122 (2003) 563-570
26. Wang Z.Y., Chen Z., Huang W., et al. Problems existing in differentiation therapy of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA). Blood Cells 19 (1993) 633-641
27. Tobita T., Takeshita A., Kitamura K., et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90 (1997) 967-973
28. Kini A.R., Peterson L.A., Tallman M.S., et al. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 97 (2001) 3919-3924
29. Banavali S.D., Goyal L., Nair R., et al. A novel, efficacious therapeutic approach to patients with acute promyelocytic leukemia (APL) using differentiating agent and metronomic chemotherapy (CT). Blood 106 (2005) 264a [abstract 900]
30. Kini A.R., Roychowdhury S., Dziuma A., et al. Vascular endothelial growth factor (VEGF) is a critical autocrine survival factor in acute promyelocytic leukemia (APL). Blood 106 (2005) 772a [abstract 2751]
31. Sassano A., Katsoulidis E., Antico G., et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Research 67 (2007) 4524-4532